Literature DB >> 17255134

Skin involvement in scleroderma--where histological and clinical scores meet.

F Verrecchia1, J Laboureau, O Verola, N Roos, R Porcher, P Bruneval, M Ertault, K Tiev, L Michel, A Mauviel, D Farge.   

Abstract

OBJECTIVES: A clinico-pathological study in diffuse systemic sclerosis (SSc) patients was performed to analyse whether the skin histological organization and the pro-fibrotic signals elicited by TGF-beta in fibroblasts vary according to the modified Rodnan skin score (mRSS).
METHODS: Twenty-seven SSc patients underwent 45 skin biopsies with simultaneous measure of mRSS before or after treatment by immunosuppressive drugs, with or without autologous peripheral haematopoietic stem cell transplantation (HSCT).
RESULTS: Double-blind optic microscopy analysis of the biopsies standard extracellular matrix stains allowed to define three histological subgroups: 6 with grade 1 weak fibrosis, 30 with grade 2 moderate fibrosis and 9 with grade 3 severe fibrosis. A significant (P < 0.0001) was identified between the grades of fibrosis and the mRSS. In skin fibroblast cultures, Smad3 phosphorylation levels, as well as mRNA steady-state levels of two transforming growth factor (TGF)-beta/Smad3 targets, COL1A2 and PAI-1, increased in parallel with the mRSS. When compared with pre-transplant values the degree of fibrosis observed after HSCT in the papillary and in the reticular dermis decreased in parallel with the fall in mRSS (n = 5 consecutive patients with repeated biopsies).
CONCLUSIONS: The histological extent of skin fibrosis correlates closely with the mRSS. Both parameters appeared to regress after HSCT. The extent of TGF-beta signalling activation in SSc skin fibroblasts appears to parallel the severity of disease.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17255134     DOI: 10.1093/rheumatology/kel451

Source DB:  PubMed          Journal:  Rheumatology (Oxford)        ISSN: 1462-0324            Impact factor:   7.580


  38 in total

1.  Proteomic analysis identification of a pattern of shared alterations in the secretome of dermal fibroblasts from systemic sclerosis and nephrogenic systemic fibrosis.

Authors:  Francesco Del Galdo; M Alexander Shaw; Sergio A Jimenez
Journal:  Am J Pathol       Date:  2010-08-19       Impact factor: 4.307

2.  High-dose immunosuppressive therapy and autologous hematopoietic cell transplantation for severe systemic sclerosis: long-term follow-up of the US multicenter pilot study.

Authors:  Richard A Nash; Peter A McSweeney; Leslie J Crofford; Muneer Abidi; Chien-Shing Chen; J David Godwin; Theodore A Gooley; Leona Holmberg; Gretchen Henstorf; C Fred LeMaistre; Maureen D Mayes; Kevin T McDonagh; Bernadette McLaughlin; Jerry A Molitor; J Lee Nelson; Howard Shulman; Rainer Storb; Federico Viganego; Mark H Wener; James R Seibold; Keith M Sullivan; Daniel E Furst
Journal:  Blood       Date:  2007-04-23       Impact factor: 22.113

Review 3.  [Current value of stem-cell transplantation in autoimmune diseases].

Authors:  I Kötter; M Schmalzing; J Henes; W Vogel; L Kanz
Journal:  Z Rheumatol       Date:  2008-12       Impact factor: 1.372

4.  Stem cell transplantation for autoimmune diseases.

Authors:  Thomas Hügle; Thomas Daikeler
Journal:  Haematologica       Date:  2010-02       Impact factor: 9.941

5.  NIH Consensus development project on criteria for clinical trials in chronic graft-versus-host disease: II. The 2014 Pathology Working Group Report.

Authors:  Howard M Shulman; Diana M Cardona; Joel K Greenson; Sangeeta Hingorani; Thomas Horn; Elisabeth Huber; Andreas Kreft; Thomas Longerich; Thomas Morton; David Myerson; Victor G Prieto; Avi Rosenberg; Nathaniel Treister; Kay Washington; Mirjana Ziemer; Steven Z Pavletic; Stephanie J Lee; Mary E D Flowers; Kirk R Schultz; Madan Jagasia; Paul J Martin; Georgia B Vogelsang; David E Kleiner
Journal:  Biol Blood Marrow Transplant       Date:  2015-01-29       Impact factor: 5.742

6.  Stem cell therapy: resetting autoimmunity or postponing the inevitable?

Authors:  Jacob M van Laar
Journal:  Ther Adv Musculoskelet Dis       Date:  2011-06       Impact factor: 5.346

Review 7.  [Systemic sclerosis. Objectives for the treatment].

Authors:  B Maurer; M Walder; R E Gay; S Gay; O Distler
Journal:  Z Rheumatol       Date:  2009-02       Impact factor: 1.372

8.  PPARγ downregulation by TGFß in fibroblast and impaired expression and function in systemic sclerosis: a novel mechanism for progressive fibrogenesis.

Authors:  Jun Wei; Asish K Ghosh; Jennifer L Sargent; Kazuhiro Komura; Minghua Wu; Qi-Quan Huang; Manu Jain; Michael L Whitfield; Carol Feghali-Bostwick; John Varga
Journal:  PLoS One       Date:  2010-11-02       Impact factor: 3.240

Review 9.  Biomarkers in Scleroderma: Progressing from Association to Clinical Utility.

Authors:  Colin Ligon; Laura K Hummers
Journal:  Curr Rheumatol Rep       Date:  2016-03       Impact factor: 4.592

10.  The role of B cells in systemic sclerosis.

Authors:  Marina D Kraaij; Jacob M van Laar
Journal:  Biologics       Date:  2008-09
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.